Aktis Oncology, Inc.
Aktis Oncology, Inc.
Aktis Oncology, Inc. (AKTS) — SEC Financial Statements & Analysis
Aktis Oncology, Inc. (AKTS) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|
Common Stock | 53 | |||||
Assets | ||||||
Assets Current | ||||||
Cash And Cash Equivalents At Carrying Value | 372 | |||||
Marketable Securities | 167 | |||||
Prepaid Expense And Other Assets Current | 5 | |||||
Assets Current | 544 | |||||
Property Plant And Equipment Net | 15 | |||||
Operating Lease Right Of Use Asset | 13 | |||||
Restricted Cash Equivalents Noncurrent | 1 | |||||
Other Assets | 4 | |||||
Assets | 577 | |||||
Liabilities And Stockhold… | ||||||
Liabilities Current | ||||||
Accounts Payable Current | 1 | |||||
Accrued Liabilities Current | 6 | |||||
Deferred Revenue Current | 19 | |||||
Operating Lease Liability Current | 1 | |||||
Liabilities Current | 28 | |||||
Deferred Revenue Noncurrent | 33 | |||||
Operating Lease Liability Noncurrent | 10 | |||||
Liabilities | 71 | |||||
Stockholders Equity Inclu… | ||||||
Stockholders Equity | ||||||
Additional Paid In Capital Common Stock | 681 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -0 | |||||
Retained Earnings Accumulated Deficit | -175 | |||||
Stockholders Equity | 506 | |||||
Liabilities And Stockholders Equity | 577 | |||||
Series Seed Redeemable Convertible Preferred Stock | 0 | |||||
Series A Redeemable Convertible Preferred Stock | 0 | |||||
Series B Redeemable Convertible Preferred Stock | 0 | |||||
Partner Redeemable Convertible Preferred Stock | 0 | |||||
Common Class A | 0 | |||||
Common Stock No Par Value | 0 | |||||
Common Stock Shares Authorized | 480 | |||||
Common Stock Shares Issued | 53 | |||||
Shares Outstanding | 53 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month |
|---|---|---|---|
| 2026 | 3.28% | 73.84% | - |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | |||
Subscribe to unlock 17+ years of financial data and 50+ calculated metrics
Subscribe to unlock 17+ years of data and 50+ calculated metrics
Performance and Valuation Metrics
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data